AstraZeneca PLC (AZN)vsKoninklijke Philips NV ADR (PHG)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
PHG
Koninklijke Philips NV ADR
$26.11
+0.46%
HEALTHCARE · Cap: $25.76B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 243% more annual revenue ($60.44B vs $17.64B). AZN leads profitability with a 17.2% profit margin vs 5.5%. PHG appears more attractively valued with a PEG of 0.87. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
PHG
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
-55.6%
Fair Value
$20.61
Current Price
$26.11
$5.50 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Earnings expanding 97.2% YoY
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Distress zone — elevated risk
5.5% margin — thin
Revenue declined 4.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : PHG
The strongest argument for PHG centers on EPS Growth, PEG Ratio, Price/Book. PEG of 0.87 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : PHG
The primary concerns for PHG are Altman Z-Score, Profit Margin, Revenue Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while PHG is a value play — different risk/reward profiles.
PHG carries more volatility with a beta of 0.93 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 57/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Koninklijke Philips NV ADR
HEALTHCARE · MEDICAL DEVICES · USA
Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?